STAT

Trump denounces ‘middlemen,’ largely spares pharma in drug pricing speech

The president who delivered an address on lowering prescription drug prices Friday wasn't the same one who, less than 18 months ago, decried pharma companies for "getting away with murder."

WASHINGTON — The president who stood in the Rose Garden Friday to deliver an address on lowering prescription drug prices wasn’t the same one who, less than 18 months ago, decried pharma companies for “getting away with murder.”

Instead, standing next to the former president of Eli Lilly USA, a substantially less bombastic President

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks